Hepatitis C treatment: latest news

Hepatitis C treatment resources

  • Hepatitis C treatment

    Effective treatments are available for hepatitis C. This field is evolving rapidly and standards of care are changing. The newest drugs can cure most people with hepatitis...

    From: Booklets

    Information level Level 2
  • Medications for hepatitis C

    The old standard of care for hepatitis C treatment for all HCV genotypes was pegylated interferon and ribavirin. Interferon works by stimulating immune system activity against HCV. There...

    From: Booklets

    Information level Level 2
  • Hepatitis C treatment for people with co-infection

    Current guidelines recommend that you start hepatitis C treatment if you have HIV and HCV co-infection with moderate or worse liver fibrosis (stage F2 to F4) and...

    From: Booklets

    Information level Level 2
  • Hepatitis C

    Hepatitis C virus (HCV) is chiefly transmitted by blood-to-blood contact. When the blood of a person with hepatitis C enters the bloodstream of another person,...

    From: Factsheets

    Information level Level 2
  • Hepatitis C

    Hepatitis C is a serious infection caused by a virus.It damages the liver, which performs essential functions in the body.Some people have hepatitis C for...

    From: The basics

    Information level Level 1
  • Hepatitis C treatment

    Deciding on the best time to take treatment for hepatitis C is not straightforward.It’s important to get support and advice to help you with this...

    From: The basics

    Information level Level 1
  • Hepatitis C virus treatment

    The current preferred treatment regimen for HCV infection is a combination of peginterferon alfa (given by injection) plus ribavirin (given orally). Interferons are human proteins that...

    From: HIV treatments directory

    Information level Level 4

Hepatitis C treatment features

Hepatitis C treatment in your own words

Hepatitis C treatment news from aidsmap

More news

Hepatitis C treatment news selected from other sources

  • Hepatitis B and C - An Action Plan for Saving Lives in Europe

    Last year, leading experts, institutions, patient organisations and pharmaceutical industry representatives met and agreed that the major recommendations produced between 2011 and 2014 should be compiled into one comprehensive document, to make it easier for policy makers, decision makers, civil society organisations and healthcare institutions to tackle viral hepatitis effectively.

    20 May 2015 | European Liver Patients Association
  • Pricing remains main barrier to HCV eradication

    Eradication is technically feasible, Dr. Edlin said during a Monday morning AASLD Clinical Symposium, but not likely until current pricing policies change.

    20 May 2015 | Digestive Disease Week News
  • Is Gilead Sciences Its Own Worst Enemy?

    Gilead's science is so good that it's actually destroying the company's business. Pharma companies, like most other businesses, make the bulk of their money through repeat business. Gilead, however, is doing something really no other drugmaker is doing -- namely curing patients of devastating infectious diseases.

    20 May 2015 | Motley Fool
  • Investing in hepatitis C drugs could save the economy billions, researchers suggest

    Researchers who examined the effect of treating hepatitis C patients with the newer generation of oral drugs suggest while these medications may cost tens of thousands of dollars for a 12-week course, they could avert billions in lost productivity.

    19 May 2015 | Medical News Today
  • The VA's Hepatitis C Problem

    Approximately 174,000 veterans in government care have been diagnosed with hepatitis C. For treatment, those veterans who know they are sick must go to the U.S. Department of Veterans Affairs (VA) and its health care services extension: the Veterans Health Administration (VHA), the largest provider of hepatitis C care in the nation. The VHA serves nearly 9 million patients at over 1,700 sites, but as Dames and many other veterans have found, treatment there is often amiss—especially when it comes to HCV.

    14 May 2015 | Newsweek
  • Sanders Asks VA to Break Patents on Gilead and AbbVie Hep C Drugs

    The ongoing debate over the cost of prescription drugs took another twist as U.S. Sen. Bernie Sanders (I-VT.) has asked the U.S. Department of Veterans Affairs to use emergency powers to break – or override – the patents on high-priced hepatitis C drugs.

    13 May 2015 | Wall Street Journal (blog)
  • WHO moves to improve access to lifesaving medicines for hepatitis C, drug-resistant TB and cancers

    WHO today published the new edition of its Model List of Essential Medicines which includes ground-breaking new treatments for hepatitis C, a variety of cancers (including breast cancer and leukaemia) and multi-drug resistant tuberculosis (TB), among others.

    11 May 2015 | World Health Organization
  • Gilead: Stop Blocking Access to Hepatitis C Treatment

    On the eve of pharmaceutical company Gilead Sciences’ annual shareholder meeting, thousands of people who have hepatitis C virus (HCV) and HCV/HIV coinfection, with their allies and physicians, have demanded that Gilead change its policies that deny access to treatment for millions of people in developing countries.

    05 May 2015 | Treatment Action Group
  • Civil Society Groups Tell UNITAID: Support access mechanisms led by civil society, not the pharmaceutical industry

    Letters from global groups express deep concerns about the Medicines Patent Pool’s entry into hepatitis C treatment.

    05 May 2015 | Hep C Coalition
  • Egypt opens first factory for locally produced Sovaldi

    Egypt's health minister said Hepatitis C is "one of the most dangerous threats to Egypt", on Sunday during the opening ceremony of a factory for the local production of Hepatitis C medication Sovaldi.

    05 May 2015 | News Egypt
More news

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.